Nausea and Pain Prophylaxis During Thyroid Surgery

NCT ID: NCT00569920

Last Updated: 2009-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Postoperative pain and nausea may diminish a patient's wellbeing, and may also delay rehabilitation, as well as increase the total cost of care and treatment. Opioids are effective drugs for treatment of pain, but with the disadvantage of side effects such as somnolence and nausea. The benefits of various types of non-opioid analgesic in reducing patients' postoperative need for opioids have been well-documented.

One non-opioid prophylaxis documented for various surgery is short-term treatment with corticosteroids. The optimal dose of corticosteroids for peroperative nausea and pain prophylaxis is not well-documented. In our study we will attempt to determine whether the aforementioned benefits of corticosteroids are valid for a group of patients undergoing thyroid surgery.

Hypothesis: Single-dose treatment with dexamethasone provides a better analgesic effect and/or reduced use of opioids than placebo in patients undergoing elective throid surgery. Higher dose of dexamethasone provide better and/or longer-lasting analgesic effects without influencing the side effect profile.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Diseases Parathyroid Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Placebo

Group Type PLACEBO_COMPARATOR

natriumchloride 0,9%

Intervention Type DRUG

iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.

2

dexamethasone "low-dose"

Group Type ACTIVE_COMPARATOR

dexamethasone

Intervention Type DRUG

IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).

3

Dexamethasone "high-dose"

Group Type ACTIVE_COMPARATOR

dexamethasone

Intervention Type DRUG

IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dexamethasone

IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).

Intervention Type DRUG

natriumchloride 0,9%

iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.

Intervention Type DRUG

dexamethasone

IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fortecortin fortecortin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inpatients scheduled for elective thyroid surgery and parathyroid surgery under general anesthesia.
* Informed consent

Exclusion Criteria

* Patients who use steroids
* Patients who use antiemetics
* Patients who use opioid analgesics
* Body weight \> 100 kg
* BMI \> 35
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sykehuset Telemark

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sykehuset Telemark

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johan Raeder, Prof. M.D

Role: STUDY_DIRECTOR

Ullevål university hospital, Oslo university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Surgery Unit, Porsgrunn, Acute Care Clinic, Telemark Hospital

Porsgrunn, Telemark, Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S-04189

Identifier Type: -

Identifier Source: secondary_id

s8197.04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thyroid and Glucose and Energy Metabolism
NCT00106119 COMPLETED PHASE2
Novel Approaches to the Treatment of Hypothyroidism
NCT06731764 RECRUITING PHASE2/PHASE3